Table 1 Baseline patient characteristics
PSA progression during initial HT (n=27) | Patient population without PSA progression (n=305) | |
|---|---|---|
patient age/years median (range) mean±SD | 74 (45–81) 72±8 | 71 (52–84) 71±6 |
follow-up period/months† median (range) mean±SD | 48 (11–113) 50±23 | 69 (2–115) 66±18 |
T stage >2a† | 74% | 25% |
Gleason score >6† | 48% | 19% |
primary PSA /ng/ml† median (range) mean±SD | 16(4–150) 31±37 | 10(1–300) 16±25 |
low risk patients*† | 7% | 37% |
intermediate risk patients**† | 7% | 28% |
high risk patients***† | 85% | 35% |
initial HT (before RT)† | 100% | 40% |
initial HT >6months† | 78% | 13% |
HDR-BT | 19% | 22% |
EBRT | 81% | 78% |